Iambic Therapeutics

Company facts

• Founded

  2019

  ConfirmedSource for founded (opens in new tab)

• Headquarters

  United States (San Diego)

  ConfirmedSource for headquarters (opens in new tab)

• Total funding

  $611.8M

  ConfirmedSource for total funding (opens in new tab)

Latest funding round

Drug discovery partners

3 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

• AbbVie Pharma

  Discovery collaboration, Sep 21, 2026

  Terms not disclosed

  ConfirmedSource for AbbVie (opens in new tab)

• Bayer Pharma

  Discovery collaboration, Jun 22, 2026

  Terms not disclosed

  ConfirmedSource for Bayer (opens in new tab)

• Takeda Pharma

  Research collaboration and license, Feb 9, 2026

  $1.7B total potential (upfront not disclosed)

  ConfirmedSource for Takeda (opens in new tab)

• Revolution Medicines Biotech

  Discovery collaboration, Jul 9, 2025

  Up to $25M in upfront and near-term milestone payments

  ConfirmedSource for Revolution Medicines (opens in new tab)

Drugs on the board

• IAM1363 (HER2 TKI) ›

  Phase 1 registry

  Company reports Phase 1/1b

  HER2-altered cancers

  Registry for IAM1363 (HER2 TKI) (opens in new tab)

Recent news

• Oct 15, 2026

  Nasdaq debut under IAM

  ReportedSource (opens in new tab)

• Oct 14, 2026

  IPO (Nasdaq: IAM): $150M

  ConfirmedSource (opens in new tab)

• Sep 21, 2026

  Multi-year AI drug discovery collaboration with AbbVie, announced the same day Iambic filed for a US IPO

  ConfirmedSource (opens in new tab)

• Jul 21, 2026

  Bayer AI drug discovery partnership with Iambic mentioned alongside Perfuse acquisition

  ReportedSource (opens in new tab)

• Jun 22, 2026

  Discovery collaboration with Bayer

  ConfirmedSource (opens in new tab)